
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. demonstrated a steady increase in the processing of EsoGuard tests, reflecting the company's potential for revenue growth, with tests increasing from 2,756 in Q2 to 2,841 in Q3. The current valuation of PAVmed is viewed as attractive, with expectations for substantial growth in its commercialized products, particularly EsoGuard and others, anticipated in 2025 and 2026. This favorable outlook is underpinned by the strong momentum in testing volume and the ongoing advancement of the company’s medical technology pipeline, which balances inherent risks with significant upside potential.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million with an earnings per share (EPS) of $(0.05), which is a slight improvement compared to the previously estimated losses but still reflects weak financial performance. The company's revenue generation remains low, particularly as its EsoGuard tests declined from 3,034 in Q1 to 2,756 in Q2, indicating a troubling downward trend in test volumes. Furthermore, the company faces significant risks, including balance sheet and liquidity concerns, regulatory hurdles, and challenges in commercialization, which amplify the negative outlook on its stock performance.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares